Bessemer Group Inc. boosted its holdings in shares of STERIS plc (NYSE:STE - Free Report) by 0.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,141,125 shares of the medical equipment provider's stock after purchasing an additional 5,434 shares during the period. Bessemer Group Inc. owned about 1.16% of STERIS worth $234,569,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Geode Capital Management LLC lifted its position in shares of STERIS by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 2,359,748 shares of the medical equipment provider's stock worth $483,775,000 after buying an additional 56,123 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of STERIS by 15.9% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,261,927 shares of the medical equipment provider's stock worth $257,585,000 after acquiring an additional 172,795 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of STERIS by 45.1% in the 4th quarter. Franklin Resources Inc. now owns 1,216,821 shares of the medical equipment provider's stock valued at $250,130,000 after purchasing an additional 378,252 shares in the last quarter. Norges Bank bought a new stake in shares of STERIS during the 4th quarter valued at approximately $238,836,000. Finally, Pictet Asset Management Holding SA grew its holdings in shares of STERIS by 3.1% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,131,374 shares of the medical equipment provider's stock valued at $232,565,000 after purchasing an additional 33,618 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.
STERIS Trading Up 0.9 %
STE traded up $2.01 during midday trading on Monday, hitting $223.10. 91,510 shares of the company were exchanged, compared to its average volume of 533,393. The firm has a market capitalization of $21.92 billion, a P/E ratio of 47.37 and a beta of 0.87. The firm's 50 day moving average price is $222.61 and its 200-day moving average price is $219.50. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. STERIS plc has a 1-year low of $197.82 and a 1-year high of $248.24.
STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. As a group, equities analysts forecast that STERIS plc will post 9.08 EPS for the current fiscal year.
STERIS Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, March 21st. Investors of record on Thursday, February 20th were paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date of this dividend was Thursday, February 20th. STERIS's dividend payout ratio is presently 48.41%.
Analyst Ratings Changes
Several research analysts have recently issued reports on STE shares. Piper Sandler upped their price target on shares of STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. JMP Securities reaffirmed a "market outperform" rating and issued a $265.00 target price on shares of STERIS in a report on Thursday. Stephens reissued an "overweight" rating and set a $240.00 price target on shares of STERIS in a research note on Thursday, February 6th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a research note on Monday, April 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $258.75.
Get Our Latest Research Report on STERIS
STERIS Profile
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
